2.Therapeutic Strategy for YMDD Mutants of Hepatitis B Virus.
Soo Hyung RYU ; Young Hwa CHUNG
The Korean Journal of Hepatology 2004;10(1):1-10
No abstract available.
Hepatitis B/*drug therapy/virology
;
Hepatitis B virus/*genetics
;
Humans
;
Mutation
7.Sequence detection of HBV-DNA P and C region in HIV/HBV superinfection subjects with drug resistance to HAART.
Biao ZHU ; Nan-ping WU ; Armin BADER ; Norbert BROCKMEYER
Journal of Zhejiang University. Medical sciences 2003;32(6):507-509
<b>OBJECTIVEb>To further study the resistance of HBV to high activity antiretrovirus therapy(HAART).
<b>METHODSb>HBV-DNA was quantitatively detected by real-time PCR in 36 HIV/HBV superinfection subjects, C region and P region HBV-DNA in high copies HBV-DNA subjects were detected by routine PCR, PCR products were purified and sequenced and compared with the HBV international Genbank using BLSAT softy ware.
<b>RESULTb>HBV-DNA was positive in 4 of 36 patients (11.1%) and another 3 had low copies(<10(4)copies/ml), one had a high HBV-DNA copies (10(7)copies/ml). It's HBV-DNA C region sequence had mutation on 2 sites (nt 2412 T/C; nt 2413 T/C) and 1 mutation P region (nt 741 A/G, also YMDD/YVDD) compared with HBV international Genbak reference sequence.
<b>CONCLUSIONb>The HBV resistance to HAART may be related with multiple genetic mutations in the C and P regain of HBV-DNA.
Antiretroviral Therapy, Highly Active ; Base Sequence ; DNA, Viral ; chemistry ; Drug Resistance, Viral ; HIV Infections ; drug therapy ; virology ; Hepatitis B ; drug therapy ; virology ; Hepatitis B virus ; genetics ; Humans ; Mutation
9.Antiviral therapy of decompensated hepatitis B virus-related cirrhosis.
Guang-Cheng CHEN ; Tao YU ; Kai-Hong HUANG ; Qi-Kui CHEN
Chinese Medical Journal 2012;125(2):373-377
<b>OBJECTIVEb>To review the development, mechanism, necessity and limitation of antiviral therapy in decompensated hepatitis B virus-related cirrhosis.
<b>DATA SOURCESb>Most information was pulled from a literature search (Pubmed 2000 to 2011) using the keywords of antiviral and decompensated hepatitis B virus-related cirrhosis. Relevant book chapters were also reviewed.
<b>STUDY SELECTIONb>Well-controlled, prospective landmark studies and review articles on antiviral therapy in decompesated hepatitis B virus-related cirrhosis were selected.
<b>RESULTSb>Specific antiviral agents not only control viral replication, which permits liver transplantation, but also improve liver function so significantly that patients could be removed from the transplant waiting list. However, the emergence of drug-resistant mutants can result in treatment failure. Combination therapy is a save-strategy in drug-resistant.
<b>CONCLUSIONSb>Although the treatment of end-stage liver disease is still a challenge worldwide, antiviral therapy has altered the natural history of hepatitis B patients with decompensated cirrhosis. The approval of the new generation of antivirals is opening new perspectives for finding the optimal antiviral treatment for patients with decompensated cirrhosis and preventing antiviral resistance. A combination of antivirals may be one of the future strategies for fulfilling these goals.
Antiviral Agents ; therapeutic use ; Hepatitis B virus ; drug effects ; pathogenicity ; Humans ; Liver Cirrhosis ; drug therapy ; virology
Result Analysis
Print
Save
E-mail